* Two Posters on SPI-1620 * One Late Breaking Poster on EOquin(R) WHO/WHAT: Spectrum Pharmaceuticals, Inc. Data Presentations on EOquin(R), and SPI-1620 WHERE: 2007 Annual Meeting of the American Association of Cancer Research (AACR) April 14-18, 2007 Los Angeles Convention Center Los Angeles, California WHEN: Monday, April 16, 2007 Abstract Number: 3118 Presentation Title: IRL-1620 Increases The Efficacy Of Radiation Treatment In Mice Bearing Lymphoma Cell Induced Tumors Time: 1:00 PM - 5:00 PM Poster Section: 24 Poster Board: 17 Authors: Luigi Lenaz, E.S. Sunila, G Kuttan, Anil Gulati. Spectrum Pharmaceuticals, Irvine, CA, Amala Cancer Research Center, Thrissur, India, Midwestern University, Downers Grove, IL Tuesday, April 17, 2007 Abstract Number: 4058 Presentation Title: ETB Receptor Agonist, IRL-1620, Enhances The Efficacy Of Cyclophosphamide And Cisplatin In Ovarian Tumor Bearing Mice. Time: 8:00 AM -12:00 PM Poster Section: 30 Poster Board: 8 Authors: N.V. Rajeshkumar, George Matwyshyn, Rajesh Shrotriya, Anil Gulati. University of Illinois at Chicago, Chicago, IL, Spectrum Pharmaceuticals, Irvine, CA Tuesday, April 17, 2007, Continued Abstract Number LB-359 Presentation Title: Effect On Wound Healing And Pharmacokinetics Of Single Intravesical Administration Of Apaziquone (EOquin(R)) Immediately Following Transurethral Resection Of Superficial Bladder Cancer Time: 1:00 PM-5:00 PM Poster Section: Late-Breaking Poster Session 2 Authors: Luigi Lenaz ; Dan Pertschuk.; Shanta Chawla; Bela Denes; Chris Nardo; Dorla Mirejovsky; L.D. Vainchtein About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. For more information, please visit our website at www.spectrumpharm.com.
Forward-looking statement -- This press release may contain forward- looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize its portfolio of drug candidates, the Company's promising pipeline, our team's ability to identify promising drugs and move these drugs through development and toward commercialization and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in- license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward- looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
COMPANY CONTACTS MEDIA CONTACT Russell Skibsted Susan Neath SVP & Chief Business Officer Porter Novelli Life Sciences 619-849-6007 Paul Arndt Manager, Investor Relations 949-788-6700
Spectrum Pharmaceuticals, Inc.Web site: http://www.spectrumpharm.com/
